Details of Disease

General Information of Disease (ID: DISM7GNX)

Disease Name	Coronavirus Disease 2019 (COVID-19)
Synonyms	severe acute respiratory syndrome coronavirus 2; SARS-CoV-2; beta-CoV; beta-CoVs; betacoronavirus; 2019-nCoV; -coronavirus; -CoVs; -CoV; SARS-coronavirus 2; 2019 novel coronavirus; 2019 novel coronavirus infection; severe acute respiratory syndrome coronavirus 2 infectious disease; coronavirus disease 2019; 2019-nCoV infection
Disease Class	1D6YCoronavirus Disease 2019
Definition	A disease caused by infection with severe acute respiratory syndrome coronavirus 2.
Disease Hierarchy	DISPEEOC: Orthocoronavirinae infectious disease DISEM33Q: Infectious disease DISM7GNX: Coronavirus Disease 2019 (COVID-19)
ICD Code	ICD-11 ICD-11: 1D6Y
Disease Identifiers	MONDO ID MONDO_0100096 MESH ID D000086382 UMLS CUI C5203670 MedGen ID 1699653 SNOMED CT ID 840539006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 109 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Acalabrutinib	DM7GCVW	Approved	NA	[1]
Adalimumab	DMQMV1B	Approved	Antibody	[2]
Almitrine	DM0SYAN	Approved	Small molecular drug	[3]
Ambroxol	DMWJE9D	Approved	Small molecular drug	[4]
Amiodarone	DMUTEX3	Approved	Small molecular drug	[5]
Amprenavir	DMLMXE0	Approved	Small molecular drug	[6]
Anakinra	DMU8KOD	Approved	NA	[7]
Anidulafungin	DM8QM5U	Approved	Small molecular drug	[8]
Arbidol	DMOQK8Z	Approved	Small molecular drug	[9]
Aspirin	DM672AH	Approved	Small molecular drug	[10]
Atorvastatin	DMF28YC	Approved	Small molecular drug	[11]
Baricitinib	DM4ONW5	Approved	Small molecular drug	[12]
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[13]
BNT162b2	DM4E70Q	Approved	Vaccine	[14]
BOCEPREVIR	DMBSHMF	Approved	Small molecular drug	[15]
Budesonide	DMJIBAW	Approved	Small molecular drug	[16]
Captopril	DM458UM	Approved	Small molecular drug	[17]
Carvedilol	DMHTEAO	Approved	Small molecular drug	[18]
Chloroquine	DMSI5CB	Approved	Small molecular drug	[19]
Chlorpromazine	DMBGZI3	Approved	Small molecular drug	[20]
Cholecalciferol	DMGU74E	Approved	Small molecular drug	[21]
Ciclesonide	DM2NA4K	Approved	Small molecular drug	[22]
Clarithromycin	DM4M1SG	Approved	Small molecular drug	[23]
Clopidogrel	DMOL54H	Approved	Small molecular drug	[24]
Colchicine	DM2POTE	Approved	Small molecular drug	[25]
Comirnaty	DMUE9ZB	Approved	Vaccine	[26]
Dapagliflozin	DM28UJG	Approved	Small molecular drug	[27]
Defibrotide	DM6CWSO	Approved	NA	[28]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[29]
Disulfiram	DMCL2OK	Approved	Small molecular drug	[30]
Dornase Alfa	DM3XU74	Approved	NA	[31]
Eculizumab	DMJGWZ7	Approved	Monoclonal antibody	[32]
Elbasvir	DMJLE18	Approved	NA	[33]
Emapalumab	DMZG5WL	Approved	Antibody	[34]
Eplerenone	DMF0NQR	Approved	Small molecular drug	[35]
Etoposide	DMNH3PG	Approved	Small molecular drug	[36]
Famotidine	DMRL3AB	Approved	Small molecular drug	[37]
Fedratinib	DM4ZBK6	Approved	Small molecular drug	[38]
Fingolimod	DM5JVAN	Approved	Small molecular drug	[39]
Fluoxetine	DM3PD2C	Approved	Small molecular drug	[40]
Fluvoxamine	DMQTJSX	Approved	Small molecular drug	[41]
Folic Acid	DMEMBJC	Approved	Small molecular drug	[42]
GSK4182136	DMYH2FI	Approved in EU	Antibody	[43]
Haloperidol	DM96SE0	Approved	Small molecular drug	[44]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[45]
Hydroxychloroquine	DMSIVND	Approved	Small molecular drug	[46]
Ibrutinib	DMHZCPO	Approved	Small molecular drug	[47]
Imatinib	DM7RJXL	Approved	Small molecular drug	[48]
Indinavir	DM0T3YH	Approved	Small molecular drug	[49]
Indomethacin	DMSC4A7	Approved	Small molecular drug	[50]
Infliximab	DMH7OIA	Approved	Antibody	[2]
Interferon beta-1a	DM1A6RV	Approved	Protein/peptide drug	[51]
Irbesartan	DMTP1DC	Approved	Small molecular drug	[52]
Isotretinoin	DM4QTBN	Approved	Small molecular drug	[53]
Ivermectin	DMDBX5F	Approved	Small molecular drug	[54]
Ketamine	DMT5HA4	Approved	Small molecular drug	[55]
Leflunomide	DMR8ONJ	Approved	Small molecular drug	[56]
Lenalidomide	DM6Q7U4	Approved	Small molecular drug	[57]
Linagliptin	DMWFJTR	Approved	Small molecular drug	[58]
Linezolid	DMGFPU2	Approved	Small molecular drug	[59]
Lisinopril	DMUOK4C	Approved	Small molecular drug	[60]
Losartan	DM72JXH	Approved	Small molecular drug	[61]
Lucinactant	DMOFFAR	Approved	NA	[62]
Mefloquine	DMWT905	Approved	Small molecular drug	[63]
Melatonin	DMKWFBT	Approved	Small molecular drug	[64]
Melphalan	DMOLNHF	Approved	Small molecular drug	[65]
Merimepodib	DM0HS92	Approved	Small molecular drug	[66]
Metformin	DM89QE1	Approved	Small molecular drug	[67]
Methotrexate	DM2TEOL	Approved	Small molecular drug	[68]
Methylene blue	DMJAPE7	Approved	NA	[69]
Methylprednisolone	DM4BDON	Approved	Small molecular drug	[70]
Montelukast	DMD157S	Approved	Small molecular drug	[71]
Mycophenolic acid	DMRBMAU	Approved	NA	[72]
Nafamostat	DMU1XOD	Approved	Small molecular drug	[73]
Naltrexone	DMUL45H	Approved	Small molecular drug	[55]
Nitazoxanide	DMOWLVG	Approved	Small molecular drug	[74]
Nitric Oxide	DM1RBYG	Approved	Small molecular drug	[75]
Nivolumab	DMAB9QE	Approved	Monoclonal antibody	[76]
Oseltamivir	DMGO72P	Approved	Small molecular drug	[77]
Oxytocin	DMDL27I	Approved	Small molecular drug	[78]
Penciclovir	DMOUMDV	Approved	Small molecular drug	[79]
Prazosin	DMCD9YG	Approved	Small molecular drug	[80]
Prednisone	DM2HG4X	Approved	Small molecular drug	[81]
Progesterone	DMUY35B	Approved	Small molecular drug	[82]
Propofol	DMB4OLE	Approved	Small molecular drug	[83]
Pyridostigmine	DM8HO1L	Approved	Small molecular drug	[84]
Ramipril	DM2R68E	Approved	Small molecular drug	[85]
Ravulizumab	DMSWNJF	Approved	Antibody	[86]
Remdesivir	DMBFZ6L	Approved	Small molecular drug	[87]
Ribavirin	DMEYLH9	Approved	Small molecular drug	[88]
Rivaroxaban	DMQMBZ1	Approved	Small molecular drug	[89]
Ruxolitinib	DM7Q98D	Approved	Small molecular drug	[90]
Sarilumab	DMOGNXY	Approved	Monoclonal antibody	[91]
Sevoflurane	DMC9O43	Approved	Small molecular drug	[92]
Siltuximab	DMGEATB	Approved	Antibody	[93]
Sirolimus	DMGW1ID	Approved	Small molecular drug	[94]
SPI-1005	DM6XFHS	Approved	Small molecular drug	[30]
Spironolactone	DM2AQ5N	Approved	Small molecular drug	[95]
Telmisartan	DMS3GX2	Approved	Small molecular drug	[96]
Thalidomide	DM70BU5	Approved	Small molecular drug	[97]
Tocilizumab	DM7J6OR	Approved	Monoclonal antibody	[98]
Tofacitinib	DMBS370	Approved	Small molecular drug	[99]
Toremifene	DMQYUWG	Approved	Small molecular drug	[100]
Tranexamic Acid	DMFI8A7	Approved	Small molecular drug	[101]
Valsartan	DMREUQ6	Approved	Small molecular drug	[102]
Verapamil	DMA7PEW	Approved	Small molecular drug	[5]
Zavegepant	DMTROUI	Approved	Small molecular drug	[103]
Favipiravir	DMBZ27L	Registered	Small molecular drug	[104]
GSK4382371A	DMAQZIH	Registered	Vaccine	[43]
------------------------------------------------------------------------------------


⏷ Show the Full List of 109 Drug(s)

This Disease is Treated as An Indication in 17 Drugs in Phase 3 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ad26-COV2-S vaccine	DM4FN7E	Phase 3 Trial	Vaccine	[105]
Adsorbed COVID-19 (inactivated) vaccine	DMMDLI2	Phase 3 Trial	Vaccine	[106]
AZD1222 vaccine	DM6L3PB	Phase 3 Trial	vaccine	[109]
Azithromycin	DMS6UOE	Phase 3 Trial	Small molecular drug	[111]
CanSino COVID-19 vaccine	DMTRFU3	Phase 3 Trial	Vaccine	[112]
DAS181	DMB0NZE	Phase 3 Trial	Protein/peptide drug	[115]
Gam-COVID-Vac vaccine	DMPZIRT	Phase 3 Trial	Vaccine	[116]
GS-441524	DMNZO7M	Phase 3 Trial	Small molecular drug	[117]
Interferon alpha-1b	DMRPO6R	Phase 3 Trial	Protein/peptide drug	[119]
Lenzilumab	DMSRIT4	Phase 3 Trial	Monoclonal antibody	[120]
mRNA-1273 vaccine	DMK5BBA	Phase 3 Trial	Vaccine	[122]
N-acetylcysteine	DMBLID9	Phase 3 Trial	Small molecular drug	[125]
Sildenafil	DM4YDAJ	Phase 3 Trial	Small molecular drug	[134]
Sinopharms inactivated vaccine	DMM8N1G	Phase 3 Trial	Vaccine	[135]
Solumedrol	DMVO2MY	Phase 3 Trial	Small molecular drug	[137]
Thymosin alpha-1	DMA4CIO	Phase 3 Trial	Protein/peptide drug	[138]
Tradipitant	DMSTZO5	Phase 3 Trial	Small molecular drug	[139]
------------------------------------------------------------------------------------


⏷ Show the Full List of 17 Drug(s)

This Disease is Treated as An Indication in 50 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Apabetalone	DMCGATN	Phase 3	NA	[107]
AZD-1222	DMFAACS	Phase 3	Vaccine	[108]
AZD3152	DM00YBR	Phase 3	Vaccine	[110]
CD24Fc	DM1ZWT7	Phase 3	Recombinant protein	[113]
Clevudine	DMR21Q3	Phase 3	Small molecular drug	[114]
GT0918	DMKW0U6	Phase 3	NA	[118]
LY-CoV555	DM6LVCQ	Phase 3	Antibody	[121]
mRNA-1273.529	DML7EMR	Phase 3	Vaccine	[123]
mRNA-1273.617	DML7H8H	Phase 3	Vaccine	[124]
NA-831	DMJQXFA	Phase 3	Small molecular drug	[126]
Nuvaxovid	DMU9D7K	Phase 3	Vaccine	[127]
NVX-CoV2373	DMJOMPM	Phase 3	Vaccine	[128]
Olokizumab	DM4Z9QI	Phase 3	Monoclonal antibody	[129]
Peginterferon lambda-1a	DMK6OFY	Phase 3	NA	[130]
Plitidepsin	DMJ8AUE	Phase 3	Small molecular drug	[131]
RTB101	DM62QTW	Phase 3	Small molecular drug	[132]
Selinexor	DMBD4K3	Phase 3	Small molecular drug	[133]
Sirukumab	DMK8AQP	Phase 3	Monoclonal antibody	[136]
VAC31518	DMCA047	Phase 3	Vaccine	[140]
Aviptadil	DMJS42H	Phase 2/3	NA	[142]
mRNA-1273.211	DM478JB	Phase 2/3	Vaccine	[124]
mRNA-1273.213	DMOJ7PO	Phase 2/3	Vaccine	[124]
OT-101	DMCTRLN	Phase 2/3	Antisense oligonucleotide	[153]
AT-527	DMARIQK	Phase 2	Small molecular drug	[158]
BMS-986253	DM42B0C	Phase 2	Antibody	[161]
BREQUINAR	DMKGM42	Phase 2	Small molecular drug	[162]
Brilacidin	DMXI9BP	Phase 2	Small molecular drug	[163]
BTL-TML	DMDIRCM	Phase 2	Small molecular drug	[164]
GBV-006	DMAV32G	Phase 2	NA	[173]
GLS-1200	DM6Y702	Phase 2	Small molecular drug	[175]
HB-AdMSC	DM5YXGL	Phase 2	Cell therapy	[177]
mRNA-1073	DMS264V	Phase 2	Vaccine	[183]
mRNA-1273.351	DMVYUU3	Phase 2	Vaccine	[184]
mRNA-1283	DM1IX9Z	Phase 2	Vaccine	[185]
PX-12	DMLVHAJ	Phase 2	Small molecular drug	[30]
Q203	DMN2XK6	Phase 2	NA	[193]
REGN-COV2	DM0KBML	Phase 2	Antibody	[195]
Tideglusib	DME4LA1	Phase 2	Small molecular drug	[30]
HB-AdMSC autologous	DMJDBTT	Phase 1/2	Cell therapy	[213]
JS016	DMGEZVF	Phase 1/2	Antibody	[216]
ABBV-744	DMTEA9C	Phase 1	NA	[225]
ADX-1612	DM86WI0	Phase 1	NA	[226]
GSK4182137	DMJJW2Y	Phase 1	Antibody	[43]
GSK4396687A	DMIAOP8	Phase 1	Vaccine	[43]
mRNA-1230	DM0RBQ5	Phase 1	Vaccine	[235]
PF-07817883	DMNX86H	Phase 1	Small molecule	[238]
PF-07926307	DMJLZQB	Phase 1	Vaccine	[239]
Suramin	DMTOUY9	Phase 1	Small molecular drug	[8]
BNT161	DMAAIJ9	Clinical trial	Vaccine	[245]
KB109	DMELU8J	Clinical Trial	NA	[246]
------------------------------------------------------------------------------------


⏷ Show the Full List of 50 Drug(s)

This Disease is Treated as An Indication in 48 Drugs in Phase 2 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
Angiotensin (1-7)	DMR84V7	Phase 2/3 Trial	Protein/peptide drug	[141]
BNT162b1 SARS-CoV-2 vaccine	DM1N65L	Phase 2/3 Trial	Vaccine	[143]
BNT162b2 SARS-CoV-2 vaccine	DM6R360	Phase 2/3 Trial	Vaccine	[143]
Calcifediol	DM82T36	Phase 2/3 Trial	Small molecular drug	[144]
Camostat mesylate	DMVLXMG	Phase 2/3 Trial	Small molecular drug	[145]
ChAdOx1 nCoV-19 vaccine	DMO4HKX	Phase 2/3 Trial	Vaccine	[146]
Heparin	DM4ZP3W	Phase 2/3 Trial	Small molecular drug	[147]
Ifenprodil	DM1VJJJ	Phase 2/3 Trial	Small molecular drug	[148]
IFX-1	DMPLQ1V	Phase 2/3 Trial	Monoclonal antibody	[149]
IMU-838	DM5UJ9P	Phase 2/3 Trial	Small molecular drug	[150]
Interferon-alpha 2b	DMQCVZ1	Phase 2/3 Trial	Protein/peptide drug	[151]
Mesenchymal stem cells	DMOUEY7	Phase 2/3 Trial	Cell therapy	[152]
Ad5-nCoV vaccine	DMGJ05P	Phase 2 Trial	Vaccine	[154]
Apilimod	DMHIS6Z	Phase 2 Trial	Small molecular drug	[155]
ArtemiC	DMS9OZZ	Phase 2 Trial	Small molecular drug	[156]
AT-001	DML3HCN	Phase 2 Trial	Small molecular drug	[157]
Avdoralimab	DMLAOHX	Phase 2 Trial	Monoclonal antibody	[159]
BLD-2660	DMKO0BQ	Phase 2 Trial	Small molecular drug	[160]
Carrimycin	DM10S8J	Phase 2 Trial	Small molecular drug	[165]
Clazakizumab	DM6ZOUV	Phase 2 Trial	Monoclonal antibody	[166]
CM4620	DMR2BZ7	Phase 2 Trial	Small molecular drug	[167]
Cyclosporin A	DMUYKBZ	Phase 2 Trial	Small molecular drug	[168]
DFV890	DM0QTUW	Phase 2 Trial	Protein/peptide drug	[169]
Dialyzable leukocyte cells	DMMU5CE	Phase 2 Trial	Cell therapy	[170]
Duvelisib	DM7USVA	Phase 2 Trial	Small molecular drug	[171]
EIDD-2801	DM50VE2	Phase 2 Trial	Small molecular drug	[172]
Gimsilumab	DMJGHXM	Phase 2 Trial	Monoclonal antibody	[174]
HB-adipose-derived mesenchymal stem cells	DMZ6PRF	Phase 2 Trial	Cell therapy	[176]
IC14	DM37CX4	Phase 2 Trial	Monoclonal antibody	[178]
Leronlimab	DMMQ6VT	Phase 2 Trial	Monoclonal antibody	[179]
LY3127804	DMAC457	Phase 2 Trial	Monoclonal antibody	[180]
MAS825	DMY7J34	Phase 2 Trial	Small molecular drug	[181]
Mesenchymal stromal cells	DMOWM9H	Phase 2 Trial	Cell therapy	[182]
NasoVAX vaccine	DMJY5X2	Phase 2 Trial	Vaccine	[186]
Nintedanib	DMMQ2OW	Phase 2 Trial	Small molecular drug	[187]
Otilimab	DM1AQLW	Phase 2 Trial	Monoclonal antibody	[188]
Peginterferon lambda alfa-1a	DMPU68I	Phase 2 Trial	Protein/peptide drug	[189]
Pegylated interferon lambda	DM4UA3J	Phase 2 Trial	Protein/peptide drug	[190]
Piclidenoson	DM2MYNQ	Phase 2 Trial	Small molecular drug	[191]
PUL-042	DMW7L0Y	Phase 2 Trial	Protein/peptide drug	[192]
Recombinant new coronavirus vaccine (CHO cell)	DMIVHYQ	Phase 2 Trial	Vaccine	[194]
Recombinant novel coronavirus vaccine	DMQOGY8	Phase 2 Trial	Vaccine	[154]
rhACE2	DMBSXR9	Phase 2 Trial	Protein/peptide drug	[196]
Ruconest	DMHEYMR	Phase 2 Trial	Protein/peptide drug	[197]
Thymosin	DM0F9EX	Phase 2 Trial	Protein/peptide drug	[198]
Triiodothyronine	DM14NKM	Phase 2 Trial	Small molecular drug	[199]
Umbilical Cord Mesenchymal Stem Cells	DMR2M43	Phase 2 Trial	Cell therapy	[200]
VERU-111	DMBXA95	Phase 2 Trial	Small molecular drug	[201]
------------------------------------------------------------------------------------


⏷ Show the Full List of 48 Drug(s)

This Disease is Treated as An Indication in 41 Drugs in Phase 1 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
Allogeneic human dental pulp stem cells	DMEN7SH	Phase 1/2 Trial	Cell therapy	[202]
Allogeneic NK cells	DM3L8BE	Phase 1/2 Trial	Cell therapy	[203]
ARCT-021 vaccine	DMNQ5X8	Phase 1/2 Trial	Vaccine	[204]
AVM0703	DMPAPV9	Phase 1/2 Trial	Small molecular drug	[205]
BBV152 vaccine	DM6LOEN	Phase 1/2 Trial	Vaccine	[206]
BNT162a1 vaccine	DMH5VW4	Phase 1/2 Trial	Vaccine	[207]
BNT162c2 SARS-CoV-2 vaccine	DM5L3NV	Phase 1/2 Trial	Vaccine	[143]
Bone Marrow-Derived Mesenchymal Stem Cells	DMFHTG0	Phase 1/2 Trial	Cell therapy	[208]
CYNK-001 cells	DM6ITC1	Phase 1/2 Trial	Cell therapy	[209]
Deferoxamine	DMG0C81	Phase 1/2 Trial	Small molecular drug	[210]
Gam-COVID-Vac Lyo vaccine	DMOPW2I	Phase 1/2 Trial	Vaccine	[211]
GX-19 vaccine	DMIP8N6	Phase 1/2 Trial	Vaccine	[212]
Inactivated SARS-CoV-2 vaccine	DMFVTRV	Phase 1/2 Trial	Vaccine	[214]
INO-4800 vaccine	DMRZS8B	Phase 1/2 Trial	Vaccine	[215]
KBP-COVID-19 vaccine	DMLYMEV	Phase 1/2 Trial	Vaccine	[217]
LEAF-4L6715	DMD5H7X	Phase 1/2 Trial	Combination drug	[218]
LEAF-4L7520	DMB4M9V	Phase 1/2 Trial	Combination drug	[218]
LV-SMENP dendritic cells vaccine	DMMG813	Phase 1/2 Trial	Vaccine	[219]
Meplazumab	DMJVFK7	Phase 1/2 Trial	Monoclonal antibody	[220]
Natural killer cells	DMKNW1S	Phase 1/2 Trial	Cell therapy	[221]
Rintatolimod	DMSDZ8U	Phase 1/2 Trial	Protein/peptide drug	[222]
TJ003234	DM0VXIM	Phase 1/2 Trial	Monoclonal antibody	[120]
Wharton's Jelly-Mesenchymal Stem Cells	DM7WGPW	Phase 1/2 Trial	Cell therapy	[223]
ZyCoV-D vaccine	DM7DNH7	Phase 1/2 Trial	Vaccine	[224]
ARCoV vaccine	DMPPODX	Phase 1 Trial	Vaccine	[227]
BacTRL-Spike vaccine	DMIYDSM	Phase 1 Trial	Vaccine	[228]
Covax-19 vaccine	DM3T7KR	Phase 1 Trial	Vaccine	[229]
Covid-19 aAPC vaccine	DM30N1S	Phase 1 Trial	Vaccine	[230]
CVnCoV vaccine	DMC3YZ1	Phase 1 Trial	Vaccine	[231]
Engineered hnCD16 iNK Cell	DMGKJ8N	Phase 1 Trial	Cell therapy	[232]
Galidesivir	DMG9C4I	Phase 1 Trial	Small molecular drug	[233]
MF59 adjuvanted SARS-CoV-2 Sclamp vaccine	DMQ48VN	Phase 1 Trial	Vaccine	[234]
MVC-COV1901 vaccine	DM330WZ	Phase 1 Trial	Vaccine	[236]
Nest mesenchymal stem cells	DM6ZJPZ	Phase 1 Trial	Cell therapy	[237]
Pathogen-specific aAPCs vaccine	DMGOU46	Phase 1 Trial	Vaccine	[230]
SARS-CoV-2 rS vaccine	DM20V8I	Phase 1 Trial	Vaccine	[240]
SCB-2019 vaccine	DMJR31Q	Phase 1 Trial	Vaccine	[241]
SnPP Protoporphyrin	DMAA0DO	Phase 1 Trial	Small molecular drug	[242]
Sulfonatoporphyrin	DMNTMN2	Phase 1 Trial	Small molecular drug	[242]
TAK-981	DM0VBRG	Phase 1 Trial	Small molecular drug	[243]
Tobacco-based vaccine	DMHGKSW	Phase 1 Trial	Vaccine	[244]
------------------------------------------------------------------------------------


⏷ Show the Full List of 41 Drug(s)

This Disease is Treated as An Indication in 6 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Hexylcarbamoyl fluorouracil	DMYNPK8	Withdrawn from market	Small molecular drug	[30]
Otamixaban	DMGOPMK	Discontinued in Phase 3	Small molecular drug	[247]
ONO-5334	DMWS7C2	Discontinued in Phase 2	NA	[155]
Relacatib	DMLJEFH	Discontinued in Phase 2	Small molecular drug	[247]
EMODIN	DMAEDQG	Terminated	Small molecular drug	[251]
MDL-28170	DMYK31O	Terminated	Small molecular drug	[155]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

This Disease is Treated as An Indication in 5 Preclinical Drugs

Drug Name	Drug ID	Highest Status	Drug Type	REF
Brensocatib	DMT2C78	Preclinical	Small molecular drug	[248]
GC376	DMR1CLY	Preclinical	Small molecular drug	[15]
Li-Key peptide vaccine	DMK3CM1	Preclinical	Vaccine	[186]
PMID26868298-compound-N3	DMQFUCD	Preclinical	Small molecular drug	[30]
TNX-1800 vaccine	DMOB06G	Preclinical	Vaccine	[250]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
mRNA-1287	DMR4BX3	Preclinical	Vaccine	[249]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 31 Investigative Agents

Drug Name	Drug ID	Highest Status	Drug Type	REF
4E2Rcat	DMD6ROZ	Investigative	Small molecular drug	[252]
Anti-SARS-CoV-2 REGN-COV2 vaccine	DMAAHOF	Investigative	Vaccine	[253]
BXT-25	DMHO1OS	Investigative	Protein/peptide drug	[254]
Camrelizumab	DMVAP4T	Investigative	Monoclonal antibody	[198]
COVID-19 S-Trimer vaccine	DMWW3XE	Investigative	Vaccine	[255]
DBET6	DMNR5M0	Investigative	Small molecular drug	[256]
E-52862	DMLZU09	Investigative	Small molecular drug	[257]
EIDD-1931	DMJONRK	Investigative	Small molecular drug	[172]
Equilin	DM2Q19U	Investigative	Small molecular drug	[258]
I-432	DM7K52X	Investigative	Small molecular drug	[247]
JQ1	DM3XQDH	Investigative	Small molecular drug	[225]
Linear DNA vaccine	DMZ2JST	Investigative	Vaccine	[259]
NMS-873	DMYKZ6U	Investigative	Small molecular drug	[88]
Oxymethalone	DMQO7WJ	Investigative	Small molecular drug	[35]
PB28	DMMNQ1B	Investigative	Small molecular drug	[260]
PD-144418	DMJKH28	Investigative	Small molecular drug	[261]
Pleo zinc	DM5Q9BU	Investigative	Small molecular drug	[262]
PMID30074795-compound-2	DMBUKQF	Investigative	Small molecular drug	[263]
PMID32198291-compound11r	DMLEJ5E	Investigative	Small molecular drug	[264]
PMID32198291-compound13b	DMBAD9Q	Investigative	Small molecular drug	[264]
PMID32321856-compound-11a	DMN39V6	Investigative	Small molecular drug	[265]
PMID32321856-compound-11b	DM31QEY	Investigative	Small molecular drug	[265]
PRD_002214	DM4PUX2	Investigative	Small molecular drug	[247]
RS-PPCC	DMN3ZOD	Investigative	Small molecular drug	[266]
Sanglifehrin A	DMJA8JM	Investigative	Small molecular drug	[256]
Sapanisertib	DMYZFNH	Investigative	Small molecular drug	[267]
TMCB	DMCD2J2	Investigative	Small molecular drug	[269]
Triazavirin	DMZBU2M	Investigative	Small molecular drug	[270]
Valproic Acid	DMS49KH	Investigative	Small molecular drug	[271]
VBY-825	DMUGVNA	Investigative	Small molecular drug	[155]
Verdinexor	DM9X2IF	Investigative	Small molecular drug	[256]
------------------------------------------------------------------------------------


⏷ Show the Full List of 31 Drug(s)

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Brincidofovir	DMS0PND	Investigative	Small molecular drug	[247]
Isoarnebin 4	DM0B7NO	Investigative	Small molecular drug	[30]
Silmitasertib	DMQIBZD	Investigative	Small molecular drug	[268]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	ClinicalTrials.gov (NCT04346199) Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.. U.S. National Institutes of Health.
2	Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020 May 2;395(10234):1407-1409.
3	Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia (AIRVM-COVID)
4	COVID-19: Relief Efforts in China.
5	ClinicalTrials.gov (NCT04351763) Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms. U.S. National Institutes of Health.
6	Macrolide treatment for COVID-19: Will this be the way forward BioScience Trends Advance Publication. DOI: 10.5582/bst.2020.03058
7	ClinicalTrials.gov (NCT04364009) Anakinra for COVID-19 Respiratory Symptoms. U.S. National Institutes of Health.
8	Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid-19 infection. April.21.2020. Doi: 10.31219/osf.io/urxwh
9	ClinicalTrials.gov (NCT04260594) Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
10	Protective Effect of Aspirin on COVID-19 Patients (PEAC)
11	ClinicalTrials.gov (NCT04380402) Atorvastatin in COVID-19. U.S. National Institutes of Health.
12	ClinicalTrials.gov (NCT04345289) Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia. U.S. National Institutes of Health.
13	ClinicalTrials.gov (NCT04275414) Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)
14	BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021 Mar;81(4):495-501.
15	Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. 2020. April 20. doi: https://doi.org/10.1101/2020.04.20.051581
16	Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia
17	ClinicalTrials.gov (NCT04345406) Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19. U.S. National Institutes of Health.
18	Can beta-adrenergic blockers be used in the treatment of COVID-19 Med Hypotheses. 2020 May 5;142:109809.
19	ClinicalTrials.gov (NCT04360759) Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19. U.S. National Institutes of Health.
20	ClinicalTrials.gov (NCT04366739) Repurposing of Chlorpromazine in Covid-19 Treatment. U.S. National Institutes of Health.
21	Cholecalciferol to Improve the Outcomes of COVID-19 Patients (CARED)
22	ClinicalTrials.gov (NCT04377711) A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients. U.S. National Institutes of Health.
23	Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early (ACHIEVE)
24	Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. (C-19-ACS)
25	ClinicalTrials.gov (NCT04322565) Colchicine Counteracting Inflammation in COVID-19 Pneumonia. U.S. National Institutes of Health.
26	FDA Approved Drug Products from FDA Official Website.
27	Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19)
28	ClinicalTrials.gov (NCT04335201) Defibrotide in COVID-19 Pneumonia. U.S. National Institutes of Health.
29	Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020 Jul 17. doi: 10.1056/NEJMoa2021436.
30	Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
31	ClinicalTrials.gov (NCT04359654) Nebulised Dornase Alfa for Treatment of COVID-19. U.S. National Institutes of Health.
32	ClinicalTrials.gov (NCT04346797) CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort
33	Drug Repurposing of Approved Drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for Combating COVID19. April 21, 2020.
34	ClinicalTrials.gov (NCT04324021) Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.. U.S. National Institutes of Health.
35	Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020 Mar 16;6:14.
36	ClinicalTrials.gov (NCT04356690) Etoposide in Patients With COVID-19 Infection. U.S. National Institutes of Health.
37	ClinicalTrials.gov (NCT04370262) Multi-site Adaptive Trials Using Hydroxycholoroquine for COVID-19. U.S. National Institutes of Health.
38	TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020 Mar 11. pii: S1684-1182(20)30065-7.
39	ClinicalTrials.gov (NCT04280588) Fingolimod in COVID-19
40	Fluoxetine to Reduce Intubation and Death After COVID19 Infection
41	ClinicalTrials.gov (NCT04342663) A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection. U.S. National Institutes of Health.
42	ClinicalTrials.gov (NCT04354428) Treatment for COVID-19 in High-Risk Adult Outpatients. U.S. National Institutes of Health.
43	Clinical pipeline report, company report or official report of GlaxoSmithKline
44	Sigma-1Rs are upregulated via PERK/eIF2/ATF4 pathway and execute protective function in ER stress. Biochem Biophys Res Commun. 2011 Nov 25;415(3):519-25.
45	Hydrocortisone for COVID-19 and Severe Hypoxia (COVID STEROID)
46	ClinicalTrials.gov (NCT04341727) Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection (WU352). U.S. National Institutes of Health.
47	Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
48	ClinicalTrials.gov (NCT04356495) Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19). U.S. National Institutes of Health.
49	Old Drugs for Newly Emerging Viral Disease, COVID-19: Bioinformatic Prospective
50	ClinicalTrials.gov (NCT04344457) Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19. U.S. National Institutes of Health.
51	ClinicalTrials.gov (NCT04315948) Trial of Treatments for COVID-19 in Hospitalized Adults
52	Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60. Clinical Trial;
53	ClinicalTrials.gov (NCT04361422) Isotretinoin in Treatment of COVID-19. U.S. National Institutes of Health.
54	ClinicalTrials.gov (NCT04351347) The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment. U.S. National Institutes of Health.
55	ClinicalTrials.gov (NCT04365985) Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19. U.S. National Institutes of Health.
56	ClinicalTrials.gov (NCT04361214) Leflunomide in Mild COVID-19 Patients. U.S. National Institutes of Health.
57	Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial (GETAFE)
58	ClinicalTrials.gov (NCT04371978) Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19. U.S. National Institutes of Health.
59	Therapeutic and Triage Strategies for 2019 Novel Coronavirus Disease in Fever Clinics. Lancet Respir Med. 2020 Mar;8(3):e11-e12.
60	Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219.
61	ClinicalTrials.gov (NCT04343001) Coronavirus Response - Active Support for Hospitalised Covid-19 Patients. U.S. National Institutes of Health.
62	The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19
63	ClinicalTrials.gov (NCT04347031) An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19. U.S. National Institutes of Health.
64	COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020 Jun 1;250:117583.
65	ClinicalTrials.gov (NCT04380376) Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia. U.S. National Institutes of Health.
66	The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro. April 09, 2020. doi: https://doi.org/10.1101/2020.04.07.028589
67	A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. March 2020
68	ClinicalTrials.gov (NCT04352465) Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients. U.S. National Institutes of Health.
69	ClinicalTrials.gov (NCT04370288) Clinical Application of Methylene Blue for Treatment of Covid-19 Patients. U.S. National Institutes of Health.
70	ClinicalTrials.gov (NCT04341038) Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury
71	The COvid-19 Symptom MOntelukast Trial (COSMO)
72	Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020 Mar 27;14:1022.
73	ClinicalTrials.gov (NCT04352400) Efficacy of Nafamostat in Covid-19 Patients (RACONA Study). U.S. National Institutes of Health.
74	ClinicalTrials.gov (NCT04382846) Novel Regimens in COVID-19 Treatment. U.S. National Institutes of Health.
75	ClinicalTrials.gov (NCT04290858) Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection. U.S. National Institutes of Health.
76	COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
77	ClinicalTrials.gov (NCT04261270) A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia
78	Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 (OsCOVID19)
79	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
80	Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) (PREVENT)
81	Certain corticosteroid could improve severe COVID-19, say researchers. May 20, 2020
82	ClinicalTrials.gov (NCT04365127) Progesterone for the Treatment of COVID-19 in Hospitalized Men. U.S. National Institutes of Health.
83	Propofol and sedation in patients with coronavirus disease. Am J Emerg Med. 2020 Jun 18;S0735-6757(20)30512-X.
84	ClinicalTrials.gov (NCT04343963) Pyridostigmine in Severe SARS-CoV-2 Infection. U.S. National Institutes of Health.
85	ClinicalTrials.gov (NCT04366050) Ramipril for the Treatment of COVID-19. U.S. National Institutes of Health.
86	ClinicalTrials.gov (NCT04369469) Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia. U.S. National Institutes of Health.
87	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
88	Proteomics of SARS-CoV-2-infected Host Cells Reveals Therapy Targets. Nature. 2020 May 14. doi: 10.1038/s41586-020-2332-7.
89	Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19 (COVID-PREVENT)
90	Incyte begins Phase III trial of ruxolitinib to treat Covid-19. 20.April.2020.
91	ClinicalTrials.gov (NCT04327388) Sarilumab COVID-19
92	Sevoflurane in COVID-19 ARDS (SevCov)
93	ClinicalTrials.gov (NCT04330638) Treatment of COVID-19 Patients With Anti-interleukin Drugs. U.S. National Institutes of Health.
94	ClinicalTrials.gov (NCT04341675) Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia. U.S. National Institutes of Health.
95	Spironolactone in Covid-19 Induced ARDS
96	ClinicalTrials.gov (NCT04359953) Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19. U.S. National Institutes of Health.
97	ClinicalTrials.gov (NCT04273529) The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia. U.S. National Institutes of Health.
98	ClinicalTrials.gov (NCT04320615) A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health.
99	ClinicalTrials.gov (NCT04332042) TOFAcitinib in SARS-CoV2 Pneumonia. U.S. National Institutes of Health.
100	Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. June 5, 2020.
101	Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients (TCInpatient)
102	Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease
103	Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
104	ClinicalTrials.gov (NCT04336904) Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
105	A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)
106	Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)
107	Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent PublicationEpigenetic BET-inhibition to combat COVID-19. Mar 24, 2020.
108	ClinicalTrials.gov (NCT04540393) AZD1222 Vaccine for the Prevention of COVID-19. U.S. National Institutes of Health.
109	Oxford COVID-19 vaccine programme opens for clinical trial recruitment. Mar 27, 2020.
110	ClinicalTrials.gov (NCT05648110) A Phase I/III Randomized, Double Blind Study to Evaluate the Safety, Efficacy and Neutralizing Activity of AZD5156/AZD3152 for Pre Exposure Prophylaxis of COVID 19 in Participants With Conditions Causing Immune Impairment. Sub-study: Phase II Open Label Sub-study to Evaluate the Safety, PK, and Neutralizing Activity of AZD3152 for Pre-exposure Prophylaxis of COVID-19. U.S.National Institutes of Health.
111	ClinicalTrials.gov (NCT04332107) Azithromycin for COVID-19 Treatment in Outpatients Nationwide. U.S. National Institutes of Health.
112	Chinas coronavirus vaccines are leaping ahead but face challenges as virus wanes. Jul 31, 2020
113	ClinicalTrials.gov (NCT04317040) CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment (SAC-COVID). U.S. National Institutes of Health.
114	ClinicalTrials.gov (NCT04347915) The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19. U.S. National Institutes of Health.
115	ClinicalTrials.gov (NCT03808922) Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study. U.S. National Institutes of Health.
116	Putin Approves First Covid-19 Vaccine Even as Trials Go On. Aug 11, 2020.
117	Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health. 2020 Mar 27;9:100128.
118	ClinicalTrials.gov (NCT04728802) Proxalutamide Treatment for Hospitalized COVID-19 Patients. U.S. National Institutes of Health.
119	Experimental Trial of rhIFN alpha Nasal Drops to Prevent 2019-nCOV in Medical Staff
120	ClinicalTrials.gov (NCT04351152) Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia. U.S. National Institutes of Health.
121	ClinicalTrials.gov (NCT04497987) A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (BLAZE-2). U.S. National Institutes of Health.
122	ClinicalTrials.gov (NCT04283461) Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19)
123	ClinicalTrials.gov (NCT05249829) A Phase 2/3, Randomized, Observer-blind, Active-controlled, Multicenter Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 (Prototype) Booster Vaccine. U.S.National Institutes of Health.
124	ClinicalTrials.gov (NCT04927065) A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants. U.S.National Institutes of Health.
125	ClinicalTrials.gov (NCT04279197) Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu. U.S. National Institutes of Health.
126	ClinicalTrials.gov (NCT04540185) A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19 (OPV-NA831). U.S. National Institutes of Health.
127	ClinicalTrials.gov (NCT05236491) COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases. U.S.National Institutes of Health.
128	Clinical pipeline report, company report or official report of Novavax.
129	ClinicalTrials.gov (NCT04380519) Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). U.S. National Institutes of Health.
130	ClinicalTrials.gov (NCT04354259) Interferon Lambda for Immediate Antiviral Therapy at Diagnosis. U.S. National Institutes of Health.
131	ClinicalTrials.gov (NCT04382066) Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19. U.S. National Institutes of Health.
132	ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
133	ClinicalTrials.gov (NCT04349098) Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection. U.S. National Institutes of Health.
134	ClinicalTrials.gov (NCT04304313) A Pilot Study of Sildenafil in COVID-19. U.S. National Institutes of Health.
135	China's Sinopharm touts 100% antibody response for COVID-19 vaccine it's already giving to workers. Jun 16, 2020.
136	ClinicalTrials.gov (NCT04380961) A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19. U.S. National Institutes of Health.
137	Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome (MP-C19)
138	Thymosin Alpha 1 to Prevent COVID-19 Infection in Elderly Renal Dialysis Patients (Ta1)
139	ClinicalTrials.gov (NCT04326426) ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection. U.S. National Institutes of Health.
140	ClinicalTrials.gov (NCT04908722) A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults. U.S.National Institutes of Health.
141	ClinicalTrials.gov (NCT04332666) Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial. U.S. National Institutes of Health.
142	ClinicalTrials.gov (NCT04311697) Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure (COVID-AIV). U.S. National Institutes of Health.
143	Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults
144	Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome (COVIDIOL)
145	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8.
146	ClinicalTrials.gov (NCT04324606) A Study of a Candidate COVID-19 Vaccine (COV001)
147	Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020 Dec;9(1):727-732.
148	ClinicalTrials.gov (NCT04382924) Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized Patients. U.S. National Institutes of Health.
149	ClinicalTrials.gov (NCT04333420) Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health.
150	ClinicalTrials.gov (NCT04379271) A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19). U.S. National Institutes of Health.
151	ClinicalTrials.gov (NCT04293887) Efficacy and Safety of IFN-2 in the Treatment of Novel Coronavirus Patients. U.S. National Institutes of Health.
152	ClinicalTrials.gov (NCT04288102) Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19). U.S. National Institutes of Health.
153	ClinicalTrials.gov (NCT04801017) A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects. U.S. National Institutes of Health.
154	ClinicalTrials.gov (NCT04341389) A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector). U.S. National Institutes of Health.
155	A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. April 17, 2020.
156	ClinicalTrials.gov (NCT04382040) A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19. U.S. National Institutes of Health.
157	ClinicalTrials.gov (NCT04365699) Cardiovascular Effects of COVID-19. U.S. National Institutes of Health.
158	ClinicalTrials.gov (NCT04709835) Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19. U.S. National Institutes of Health.
159	ClinicalTrials.gov (NCT04371367) Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE ). U.S. National Institutes of Health.
160	ClinicalTrials.gov (NCT04334460) Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects. U.S. National Institutes of Health.
161	ClinicalTrials.gov (NCT04347226) Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. U.S. National Institutes of Health.
162	ClinicalTrials.gov (NCT04575038) CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 (CRISIS2). U.S. National Institutes of Health.
163	Innovation Pharmaceuticals Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line. June 17, 2020.
164	ClinicalTrials.gov (NCT04522830) A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19 (BTL-TML-COVID). U.S. National Institutes of Health.
165	ClinicalTrials.gov (NCT04286503) The Clinical Study of Carrimycin on Treatment Patients With COVID-19
166	ClinicalTrials.gov (NCT04348500) Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease. U.S. National Institutes of Health.
167	ClinicalTrials.gov (NCT04345614) A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health.
168	Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia. Reumatol Clin. 2020 Apr 16;S1699-258X(20)30044-9.
169	ClinicalTrials.gov (NCT04382053) Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia. U.S. National Institutes of Health.
170	ClinicalTrials.gov (NCT04379479) Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T). U.S. National Institutes of Health.
171	ClinicalTrials.gov (NCT04372602) Duvelisib to Combat COVID-19. U.S. National Institutes of Health.
172	An Orally Bioavailable Broad-Spectrum Antiviral Inhibits SARS-CoV-2 in Human Airway Epithelial Cell Cultures and Multiple Coronaviruses in Mice. Sci Transl Med. 2020 Apr 6;eabb5883.
173	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
174	A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
175	ClinicalTrials.gov (NCT04408183) GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel. U.S. National Institutes of Health.
176	ClinicalTrials.gov (NCT04349631) A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19. U.S. National Institutes of Health.
177	ClinicalTrials.gov (NCT04362189) Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19. U.S. National Institutes of Health.
178	IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19)
179	ClinicalTrials.gov (NCT04343651) Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
180	ClinicalTrials.gov (NCT04342897) A Study of LY3127804 in Participants With COVID-19. U.S. National Institutes of Health.
181	Study of Efficacy and Safety of MAS825 in Patients With COVID-19 (MAS-COVID)
182	ClinicalTrials.gov (NCT04366271) Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19. U.S. National Institutes of Health.
183	ClinicalTrials.gov (NCT05375838) Phase 1/2, Randomized, Stratified, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1073 (SARS-CoV-2 and Influenza Vaccine) Compared to Co-administered mRNA-1010 (Influenza) and mRNA-1273 (SARS-CoV-2) Vaccines and to mRNA- 1010 Vaccine and mRNA-1273 Vaccine Alone in Healthy Adults 18-75 Years of Age. U.S.National Institutes of Health.
184	ClinicalTrials.gov (NCT04405076) A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older. U.S.National Institutes of Health.
185	ClinicalTrials.gov (NCT05137236) A Phase 2A, Randomized, Stratified, Observer-Blind Study to Evaluate the Immunogenicity and Safety of mRNA-1283 Vaccine Boosters for SARS-CoV-2. U.S.National Institutes of Health.
186	DRAFT landscape of COVID-19 candidate vaccines. 20 April 2020
187	ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.
188	ClinicalTrials.gov (NCT04376684) Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease. U.S. National Institutes of Health.
189	ClinicalTrials.gov (NCT04344600) Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection. U.S. National Institutes of Health.
190	ClinicalTrials.gov (NCT04343976) Pegylated Interferon Lambda Treatment for COVID-19. U.S. National Institutes of Health.
191	ClinicalTrials.gov (NCT04333472) Piclidenoson for Treatment of COVID-19. U.S. National Institutes of Health.
192	ClinicalTrials.gov (NCT04312997) The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection. U.S. National Institutes of Health.
193	ClinicalTrials.gov (NCT04847583) A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients. U.S. National Institutes of Health.
194	Clinical Study of Recombinant Novel Coronavirus Vaccine
195	ClinicalTrials.gov (NCT04852978) COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers. U.S. National Institutes of Health.
196	ClinicalTrials.gov (NCT04335136) Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19. U.S. National Institutes of Health.
197	Pharming reports encouraging results from use of RUCONEST in COVID-19 patients. April 21, 2020.
198	ClinicalTrials.gov (NCT04268537) Immunoregulatory Therapy for 2019-nCoV. U.S. National Institutes of Health.
199	ClinicalTrials.gov (NCT04348513) Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection. U.S. National Institutes of Health.
200	ClinicalTrials.gov (NCT04269525) Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia. U.S. National Institutes of Health.
201	VERU-111, an Oral, Next Generation, First-In-Class Small Molecule for the Potential Treatment of COVID-19. May 15, 2020.
202	ClinicalTrials.gov (NCT04336254) Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients. U.S. National Institutes of Health.
203	ClinicalTrials.gov (NCT04344548) Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia. U.S. National Institutes of Health.
204	Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects
205	ClinicalTrials.gov (NCT04366115) Evaluating AVM0703 for Treatment of COVID-19. U.S. National Institutes of Health.
206	Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers (BBV152)
207	ClinicalTrials.gov (NCT04380701) A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults. U.S. National Institutes of Health.
208	ClinicalTrials.gov (NCT04346368) Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19). U.S. National Institutes of Health.
209	ClinicalTrials.gov (NCT04365101) Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNK-001-COVID-19). U.S. National Institutes of Health.
210	ClinicalTrials.gov (NCT04333550) Application of Desferal to Treat COVID-19. U.S. National Institutes of Health.
211	An Open Study of the Safety, Tolerability and Immunogenicity of "Gam-COVID-Vac Lyo" Vaccine Against COVID-19
212	Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults
213	ClinicalTrials.gov (NCT03691909) A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis. U.S.National Institutes of Health.
214	Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19
215	ClinicalTrials.gov (NCT04336410) Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
216	ClinicalTrials.gov (NCT04780321) JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects. U.S. National Institutes of Health.
217	KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers
218	A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease (LEAF-4L7520/4L6715) (LEAF-4L6715)
219	ClinicalTrials.gov (NCT04276896) Immunity and Safety of Covid-19 Synthetic Minigene Vaccine
220	ClinicalTrials.gov (NCT04275245) Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia. U.S. National Institutes of Health.
221	ClinicalTrials.gov (NCT04324996) A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19. U.S. National Institutes of Health.
222	ClinicalTrials.gov (NCT04379518) Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients. U.S. National Institutes of Health.
223	ClinicalTrials.gov (NCT04313322) Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells. U.S. National Institutes of Health.
224	Zydus Cadila begins human dosing in trials of Covid-19 vaccine candidate. Jul 17, 2020.
225	Uncovering the Role of BRD2 in COVID-19. 2020-03-19
226	Clinical pipeline report, company report or official report of Aldeyra Therapeutics
227	China's first COVID-19 mRNA vaccine approved for clinical trials. June 30, 2020.
228	ClinicalTrials.gov (NCT04334980) Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19. U.S. National Institutes of Health.
229	Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
230	ClinicalTrials.gov (NCT04299724) Safety and Immunity of Covid-19 aAPC Vaccine
231	A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults
232	ClinicalTrials.gov (NCT04363346) Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia. U.S. National Institutes of Health.
233	ClinicalTrials.gov (NCT03891420) A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19. U.S. National Institutes of Health.
234	A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults
235	ClinicalTrials.gov (NCT05585632) Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age. U.S.National Institutes of Health.
236	A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901
237	ClinicalTrials.gov (NCT04315987) NestCell Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health.
238	ClinicalTrials.gov (NCT05580003) COVID-19: A MULTIPART, PHASE 1 STUDY WITH RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE-DOSE ESCALATION TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07817883 AND OPTIONAL OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE RELATIVE BIOAVAILABILITY AND FOOD EFFECT OF SOLID ORAL FORMULATION AND OPTIONAL OPEN-LABEL, NON-RANDOMIZED STUDY TO EVALUATE METABOLISM AND EXCRETION OF PF-07817883 AND OPTIONAL RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE EFFECT OF PF-07817883 ON PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY ADULT PARTICIPANTS. U.S.National Institutes of Health.
239	Clinical pipeline report, company report or official report of Pfizer
240	ClinicalTrials.gov (NCT04368988) Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant. U.S. National Institutes of Health.
241	SCB-2019 as COVID-19 Vaccine
242	ClinicalTrials.gov (NCT04371822) Efficacy of Sn-protoporphyrin IX (SnPPIX) and Sulfonatoporphyrin(TPPS)Against Covid-19. U.S. National Institutes of Health.
243	ClinicalTrials.gov (NCT03648372) A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19). U.S. National Institutes of Health.
244	Covid-19 roundup: After Trump attack, doctors, researchers flock to defend Fauci; Philip Morris-backed Medicago begins dosing tobacco-based vaccine. July 14, 2020.
245	ClinicalTrials.gov (NCT04824651) Covid-19 Vaccine Cohort in Specific Populations. U.S.National Institutes of Health.
246	Clinical pipeline report, company report or official report of Kaleido Biosciences.
247	A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020 May 1;10.1111/bph.15094.
248	Brensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial. Apr 23, 2020.
249	Clinical pipeline report, company report or official report of Moderna
250	Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
251	Naturally Occurring Anthraquinones as Potential Inhibitors of SARS-CoV-2 Main Protease: A Molecular Docking Study. May 7, 2020
252	Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J Virol. 2011 Jul;85(13):6381-9.
253	Regeneron begins first clinical trials of anti-viral antibody cocktail regn-cov2 for the treatment and prevention of COVID-19. June 11, 2020.
254	Bioxytran Seeking Partners for Late Stage Treatment of Wuhan Coronavirus using BXT-25
255	COVID-19 update: therapeutic and regulatory developments. February 25, 2020.
256	A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. March 27, 2020.
257	Synthesis and Biological Evaluation of the 1-arylpyrazole Class of (1) Receptor Antagonists: Identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862). J Med Chem. 2012 Oct 11;55(19):8211-24.
258	Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients. J Pharm Pharm Sci. 2020;23(1):75-85.
259	Pharmaceutical Technology \| Applied DNA, Takis Biotech design four Covid-19 vaccine candidates
260	Cyclohexylpiperazine Derivative PB28, a sigma2 Agonist and sigma1 Antagonist Receptor, Inhibits Cell Growth, Modulates P-glycoprotein, and Synergizes With Anthracyclines in Breast Cancer. Mol Cancer Ther. 2006 Jul;5(7):1807-16. doi: 10.1158/1535-7163.MCT-05-0402.
261	The pharmacology of the novel and selective sigma ligand, PD 144418. Neuropharmacology. 1997 Jan;36(1):51-62.
262	Potential role of zinc supplementation in prophylaxis and treatment of COVID-19. Med Hypotheses. 2020 May 25;144:109848.
263	Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle. J Med Chem. 2018 Nov 8;61(21):9473-9499.
264	Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved -ketoamide inhibitors. Science. 2020 Apr 24;368(6489):409-412.
265	Structure-based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease. Science. 2020 Apr 22;eabb4489.
266	Novel sigma receptor ligands: synthesis and biological profile. J Med Chem. 2007 Mar 8;50(5):951-61.
267	Prevent COVID-19 Severity by Repurposing mTOR Inhibitors. 2 April 2020
268	News report, company report or official report of Senhwa Biosciences, Inc. Senhwa Biosciences Silmitasertib Named as Potential COVID-19 Therapy. 2020 March 31.
269	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
270	China Tests Russian Antiviral Drug Which Might Treat Coronavirus As Moscow Warns Of Possible Mass Outbreak. February 5, 2020
271	Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid. Med Hypotheses. 2020 May 27;143:109891.
272	ClinicalTrials.gov (NCT04372082) Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19. U.S. National Institutes of Health.
273	ClinicalTrials.gov (NCT04252274) Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
274	Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia
275	ClinicalTrials.gov (NCT04321278) Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). U.S. National Institutes of Health.
276	ClinicalTrials.gov (NCT04303299) Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial
277	ClinicalTrials.gov (NCT04355052) Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus. U.S. National Institutes of Health.
278	ClinicalTrials.gov (NCT04371406) Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients. U.S. National Institutes of Health.
279	ClinicalTrials.gov (NCT04383717) Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial. U.S. National Institutes of Health.
280	ClinicalTrials.gov (NCT04331470) Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19. U.S. National Institutes of Health.
281	ClinicalTrials.gov (NCT04360356) Ivermectin and Nitazoxanide Combination Therapy for COVID-19. U.S. National Institutes of Health.
282	ClinicalTrials.gov (NCT04374032) Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection. U.S. National Institutes of Health.
283	ClinicalTrials.gov (NCT04361318) Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19. U.S. National Institutes of Health.
284	ClinicalTrials.gov (NCT04276688) Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment
285	ClinicalTrials.gov (NCT04348695) Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.. U.S. National Institutes of Health.
286	ClinicalTrials.gov (NCT04273581) The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19. U.S. National Institutes of Health.
287	ClinicalTrials.gov (NCT04374019) Novel Agents for Treatment of High-risk COVID-19 Positive Patients. U.S. National Institutes of Health.
288	Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
289	ClinicalTrials.gov (NCT04339426) Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection. U.S. National Institutes of Health.
290	ClinicalTrials.gov (NCT04291729) Evaluation of Ganovo Danoprevir Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection
291	ClinicalTrials.gov (NCT04343092) Ivermectin Adjuvant to Hydroxychloroquin and Azithromycine in COVID19 Patients. U.S. National Institutes of Health.
292	ClinicalTrials.gov (NCT04251871) Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection
293	ClinicalTrials.gov (NCT04261907) Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
294	ClinicalTrials.gov (NCT04275388) Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia